ID   FNTA_HUMAN              Reviewed;         379 AA.
AC   P49354; A6NJW0; Q53XJ9; Q9UDC1;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   10-MAY-2017, entry version 177.
DE   RecName: Full=Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha;
DE            EC=2.5.1.58 {ECO:0000269|PubMed:12036349, ECO:0000269|PubMed:12825937, ECO:0000269|PubMed:16893176, ECO:0000269|PubMed:19246009, ECO:0000269|PubMed:8419339, ECO:0000269|PubMed:8494894};
DE            EC=2.5.1.59 {ECO:0000269|PubMed:16893176};
DE   AltName: Full=CAAX farnesyltransferase subunit alpha;
DE   AltName: Full=FTase-alpha;
DE   AltName: Full=Ras proteins prenyltransferase subunit alpha;
DE   AltName: Full=Type I protein geranyl-geranyltransferase subunit alpha;
DE            Short=GGTase-I-alpha;
GN   Name=FNTA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Retina;
RX   PubMed=8276393; DOI=10.1006/geno.1993.1432;
RA   Andres D.A., Milatovich A., Ozcelik T., Wenzlau J.M., Brown M.S.,
RA   Goldstein J.L., Francke U.;
RT   "cDNA cloning of the two subunits of human CAAX farnesyltransferase
RT   and chromosomal mapping of FNTA and FNTB loci and related sequences.";
RL   Genomics 18:105-112(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), MUTAGENESIS OF LYS-164,
RP   FUNCTION, CATALYTIC ACTIVITY, AND SUBUNIT.
RX   PubMed=8419339;
RA   Andres D.A., Goldstein J.L., Ho Y.K., Brown M.S.;
RT   "Mutational analysis of alpha-subunit of protein farnesyltransferase.
RT   Evidence for a catalytic role.";
RL   J. Biol. Chem. 268:1383-1390(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), MUTAGENESIS OF ASN-199,
RP   CATALYTIC ACTIVITY, AND FUNCTION.
RC   TISSUE=Placenta;
RX   PubMed=8494894; DOI=10.1021/bi00070a028;
RA   Omer C.A., Kral A.M., Diehl R.E., Prendergast G.C., Powers S.,
RA   Allen C.M., Gibbs J.B., Kohl N.E.;
RT   "Characterization of recombinant human farnesyl-protein transferase:
RT   cloning, expression, farnesyl diphosphate binding, and functional
RT   homology with yeast prenyl-protein transferases.";
RL   Biochemistry 32:5167-5176(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Synovium;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Gloeckner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C.J., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Colon, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 24-261 (ISOFORM 2).
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-373, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-373, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) IN COMPLEX WITH FNTB, AND
RP   SUBUNIT.
RX   PubMed=11687658; DOI=10.1073/pnas.241407898;
RA   Long S.B., Hancock P.J., Kral A.M., Hellinga H.W., Beese L.S.;
RT   "The crystal structure of human protein farnesyltransferase reveals
RT   the basis for inhibition by CaaX tetrapeptides and their mimetics.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:12948-12953(2001).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) IN COMPLEX WITH FNTB, SUBUNIT,
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=12036349; DOI=10.1021/jm010531d;
RA   Bell I.M., Gallicchio S.N., Abrams M., Beese L.S., Beshore D.C.,
RA   Bhimnathwala H., Bogusky M.J., Buser C.A., Culberson J.C., Davide J.,
RA   Ellis-Hutchings M., Fernandes C., Gibbs J.B., Graham S.L.,
RA   Hamilton K.A., Hartman G.D., Heimbrook D.C., Homnick C.F., Huber H.E.,
RA   Huff J.R., Kassahun K., Koblan K.S., Kohl N.E., Lobell R.B.,
RA   Lynch J.J. Jr., Robinson R., Rodrigues A.D., Taylor J.S., Walsh E.S.,
RA   Williams T.M., Zartman C.B.;
RT   "3-aminopyrrolidinone farnesyltransferase inhibitors: design of
RT   macrocyclic compounds with improved pharmacokinetics and excellent
RT   cell potency.";
RL   J. Med. Chem. 45:2388-2409(2002).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) IN COMPLEX WITH FNTB, SUBUNIT,
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=12825937; DOI=10.1021/jm020587n;
RA   deSolms S.J., Ciccarone T.M., MacTough S.C., Shaw A.W., Buser C.A.,
RA   Ellis-Hutchings M., Fernandes C., Hamilton K.A., Huber H.E.,
RA   Kohl N.E., Lobell R.B., Robinson R.G., Tsou N.N., Walsh E.S.,
RA   Graham S.L., Beese L.S., Taylor J.S.;
RT   "Dual protein farnesyltransferase-geranylgeranyltransferase-I
RT   inhibitors as potential cancer chemotherapeutic agents.";
RL   J. Med. Chem. 46:2973-2984(2003).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) IN COMPLEX WITH FNTB, AND
RP   SUBUNIT.
RX   PubMed=15170324; DOI=10.1021/bi049723b;
RA   Reid T.S., Beese L.S.;
RT   "Crystal structures of the anticancer clinical candidates R115777
RT   (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase
RT   suggest a mechanism of FTI selectivity.";
RL   Biochemistry 43:6877-6884(2004).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) IN COMPLEX WITH FNTB, AND
RP   SUBUNIT.
RX   PubMed=15451670; DOI=10.1016/j.jmb.2004.08.056;
RA   Reid T.S., Terry K.L., Casey P.J., Beese L.S.;
RT   "Crystallographic analysis of CaaX prenyltransferases complexed with
RT   substrates defines rules of protein substrate selectivity.";
RL   J. Mol. Biol. 343:417-433(2004).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) IN COMPLEX WITH FNTB, FUNCTION,
RP   SUBUNIT, AND CATALYTIC ACTIVITY.
RX   PubMed=16893176; DOI=10.1021/bi060295e;
RA   Terry K.L., Casey P.J., Beese L.S.;
RT   "Conversion of protein farnesyltransferase to a
RT   geranylgeranyltransferase.";
RL   Biochemistry 45:9746-9755(2006).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 1-379 IN COMPLEX WITH FNTB,
RP   SUBUNIT, FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=19246009; DOI=10.1016/j.chembiol.2009.01.014;
RA   Hast M.A., Fletcher S., Cummings C.G., Pusateri E.E., Blaskovich M.A.,
RA   Rivas K., Gelb M.H., Van Voorhis W.C., Sebti S.M., Hamilton A.D.,
RA   Beese L.S.;
RT   "Structural basis for binding and selectivity of antimalarial and
RT   anticancer ethylenediamine inhibitors to protein
RT   farnesyltransferase.";
RL   Chem. Biol. 16:181-192(2009).
CC   -!- FUNCTION: Essential subunit of both the farnesyltransferase and
CC       the geranylgeranyltransferase complex. Contributes to the transfer
CC       of a farnesyl or geranylgeranyl moiety from farnesyl or
CC       geranylgeranyl diphosphate to a cysteine at the fourth position
CC       from the C-terminus of several proteins having the C-terminal
CC       sequence Cys-aliphatic-aliphatic-X. May positively regulate
CC       neuromuscular junction development downstream of MUSK via its
CC       function in RAC1 prenylation and activation.
CC       {ECO:0000269|PubMed:12036349, ECO:0000269|PubMed:12825937,
CC       ECO:0000269|PubMed:16893176, ECO:0000269|PubMed:19246009,
CC       ECO:0000269|PubMed:8419339, ECO:0000269|PubMed:8494894}.
CC   -!- CATALYTIC ACTIVITY: Farnesyl diphosphate + protein-cysteine = S-
CC       farnesyl protein + diphosphate. {ECO:0000269|PubMed:12036349,
CC       ECO:0000269|PubMed:12825937, ECO:0000269|PubMed:16893176,
CC       ECO:0000269|PubMed:19246009, ECO:0000269|PubMed:8419339,
CC       ECO:0000269|PubMed:8494894}.
CC   -!- CATALYTIC ACTIVITY: Geranylgeranyl diphosphate + protein-cysteine
CC       = S-geranylgeranyl-protein + diphosphate.
CC       {ECO:0000269|PubMed:16893176}.
CC   -!- ENZYME REGULATION: Activated by the AGRIN-induced phosphorylation
CC       which is mediated by MUSK. {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with MUSK; the interaction is direct and
CC       mediates AGRIN-induced phosphorylation of FNTA (By similarity).
CC       Heterodimer of FNTA and FNTB (farnesyltransferase). Heterodimer of
CC       FNTA and PGGT1B (geranylgeranyltransferase). {ECO:0000250,
CC       ECO:0000269|PubMed:11687658, ECO:0000269|PubMed:12036349,
CC       ECO:0000269|PubMed:12825937, ECO:0000269|PubMed:15170324,
CC       ECO:0000269|PubMed:15451670, ECO:0000269|PubMed:16893176,
CC       ECO:0000269|PubMed:19246009, ECO:0000269|PubMed:8419339}.
CC   -!- INTERACTION:
CC       P49356:FNTB; NbExp=11; IntAct=EBI-602336, EBI-602349;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P49354-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P49354-2; Sequence=VSP_036468;
CC   -!- PTM: Phosphorylated. Phosphorylation is mediated by MUSK upon
CC       AGRIN stimulation and results in the activation of FNTA (By
CC       similarity). {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein prenyltransferase subunit alpha
CC       family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L10413; AAA86285.1; -; mRNA.
DR   EMBL; L00634; AAA35853.1; -; mRNA.
DR   EMBL; AC110275; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BT009854; AAP88856.1; -; mRNA.
DR   EMBL; AK292121; BAF84810.1; -; mRNA.
DR   EMBL; AC113191; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC017029; AAH17029.2; -; mRNA.
DR   EMBL; BC084566; AAH84566.1; -; mRNA.
DR   EMBL; AL698961; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS6140.1; -. [P49354-1]
DR   PIR; A47659; A47659.
DR   RefSeq; NP_002018.1; NM_002027.2. [P49354-1]
DR   UniGene; Hs.370312; -.
DR   PDB; 1JCQ; X-ray; 2.30 A; A=1-379.
DR   PDB; 1LD7; X-ray; 2.00 A; A=1-379.
DR   PDB; 1LD8; X-ray; 1.80 A; A=1-379.
DR   PDB; 1MZC; X-ray; 2.00 A; A=1-379.
DR   PDB; 1S63; X-ray; 1.90 A; A=1-379.
DR   PDB; 1SA4; X-ray; 2.10 A; A=1-379.
DR   PDB; 1TN6; X-ray; 1.80 A; A=1-379.
DR   PDB; 2F0Y; X-ray; 2.70 A; A=1-379.
DR   PDB; 2H6F; X-ray; 1.50 A; A=1-379.
DR   PDB; 2H6G; X-ray; 1.85 A; A=1-379.
DR   PDB; 2H6H; X-ray; 1.80 A; A=1-379.
DR   PDB; 2H6I; X-ray; 3.00 A; A=1-379.
DR   PDB; 2IEJ; X-ray; 1.80 A; A=1-379.
DR   PDB; 3E37; X-ray; 1.80 A; A=1-379.
DR   PDBsum; 1JCQ; -.
DR   PDBsum; 1LD7; -.
DR   PDBsum; 1LD8; -.
DR   PDBsum; 1MZC; -.
DR   PDBsum; 1S63; -.
DR   PDBsum; 1SA4; -.
DR   PDBsum; 1TN6; -.
DR   PDBsum; 2F0Y; -.
DR   PDBsum; 2H6F; -.
DR   PDBsum; 2H6G; -.
DR   PDBsum; 2H6H; -.
DR   PDBsum; 2H6I; -.
DR   PDBsum; 2IEJ; -.
DR   PDBsum; 3E37; -.
DR   DisProt; DP00558; -.
DR   ProteinModelPortal; P49354; -.
DR   SMR; P49354; -.
DR   BioGrid; 108625; 26.
DR   IntAct; P49354; 14.
DR   MINT; MINT-238861; -.
DR   STRING; 9606.ENSP00000303423; -.
DR   BindingDB; P49354; -.
DR   ChEMBL; CHEMBL271; -.
DR   DrugBank; DB08180; 2-[METHYL-(5-GERANYL-4-METHYL-PENT-3-ENYL)-AMINO]-ETHYL-DIPHOSPHATE.
DR   DrugBank; DB06953; 2-CHLORO-5-(3-CHLORO-PHENYL)-6-[(4-CYANO-PHENYL)-(3-METHYL-3H-IMIDAZOL-4-YL)- METHOXYMETHYL]-NICOTINONITRILE.
DR   DrugBank; DB07227; 4-[(5-{[4-(3-CHLOROPHENYL)-3-OXOPIPERAZIN-1-YL]METHYL}-1H-IMIDAZOL-1-YL)METHYL]BENZONITRILE.
DR   DrugBank; DB07895; ALPHA-HYDROXYFARNESYLPHOSPHONIC ACID.
DR   DrugBank; DB04893; AZD3409.
DR   DrugBank; DB07780; FARNESYL DIPHOSPHATE.
DR   DrugBank; DB07841; GERANYLGERANYL DIPHOSPHATE.
DR   iPTMnet; P49354; -.
DR   PhosphoSitePlus; P49354; -.
DR   SwissPalm; P49354; -.
DR   BioMuta; FNTA; -.
DR   DMDM; 1346694; -.
DR   EPD; P49354; -.
DR   MaxQB; P49354; -.
DR   PaxDb; P49354; -.
DR   PeptideAtlas; P49354; -.
DR   PRIDE; P49354; -.
DR   DNASU; 2339; -.
DR   Ensembl; ENST00000302279; ENSP00000303423; ENSG00000168522. [P49354-1]
DR   GeneID; 2339; -.
DR   KEGG; hsa:2339; -.
DR   UCSC; uc003xps.5; human. [P49354-1]
DR   CTD; 2339; -.
DR   DisGeNET; 2339; -.
DR   GeneCards; FNTA; -.
DR   HGNC; HGNC:3782; FNTA.
DR   HPA; CAB010149; -.
DR   HPA; HPA018830; -.
DR   MIM; 134635; gene.
DR   neXtProt; NX_P49354; -.
DR   OpenTargets; ENSG00000168522; -.
DR   PharmGKB; PA28199; -.
DR   eggNOG; KOG0530; Eukaryota.
DR   eggNOG; COG5536; LUCA.
DR   GeneTree; ENSGT00550000074935; -.
DR   HOGENOM; HOG000188957; -.
DR   HOVERGEN; HBG004498; -.
DR   InParanoid; P49354; -.
DR   KO; K05955; -.
DR   OMA; RQWAIRS; -.
DR   OrthoDB; EOG091G0CNT; -.
DR   PhylomeDB; P49354; -.
DR   TreeFam; TF313038; -.
DR   BRENDA; 2.5.1.58; 2681.
DR   Reactome; R-HSA-111465; Apoptotic cleavage of cellular proteins.
DR   Reactome; R-HSA-2514859; Inactivation, recovery and regulation of the phototransduction cascade.
DR   SIGNOR; P49354; -.
DR   ChiTaRS; FNTA; human.
DR   EvolutionaryTrace; P49354; -.
DR   GeneWiki; FNTA; -.
DR   GenomeRNAi; 2339; -.
DR   PMAP-CutDB; P49354; -.
DR   PRO; PR:P49354; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000168522; -.
DR   CleanEx; HS_FNTA; -.
DR   ExpressionAtlas; P49354; baseline and differential.
DR   Genevisible; P49354; HS.
DR   GO; GO:0005953; C:CAAX-protein geranylgeranyltransferase complex; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005875; C:microtubule associated complex; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IEA:GOC.
DR   GO; GO:0005965; C:protein farnesyltransferase complex; IDA:UniProtKB.
DR   GO; GO:0030548; F:acetylcholine receptor regulator activity; IEA:Ensembl.
DR   GO; GO:0043014; F:alpha-tubulin binding; IDA:BHF-UCL.
DR   GO; GO:0004662; F:CAAX-protein geranylgeranyltransferase activity; IEA:UniProtKB-EC.
DR   GO; GO:0008017; F:microtubule binding; IDA:BHF-UCL.
DR   GO; GO:0004660; F:protein farnesyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0004661; F:protein geranylgeranyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0004663; F:Rab geranylgeranyltransferase activity; IEA:Ensembl.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IEA:Ensembl.
DR   GO; GO:0097194; P:execution phase of apoptosis; TAS:Reactome.
DR   GO; GO:0045213; P:neurotransmitter receptor metabolic process; IEA:Ensembl.
DR   GO; GO:0090045; P:positive regulation of deacetylase activity; IDA:BHF-UCL.
DR   GO; GO:0090044; P:positive regulation of tubulin deacetylation; IDA:BHF-UCL.
DR   GO; GO:0018343; P:protein farnesylation; IDA:UniProtKB.
DR   GO; GO:0018344; P:protein geranylgeranylation; IDA:UniProtKB.
DR   GO; GO:0022400; P:regulation of rhodopsin mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0071340; P:skeletal muscle acetylcholine-gated channel clustering; IEA:Ensembl.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; TAS:ProtInc.
DR   InterPro; IPR002088; Prenyl_trans_a.
DR   Pfam; PF01239; PPTA; 5.
DR   PROSITE; PS51147; PFTA; 5.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Phosphoprotein; Prenyltransferase; Reference proteome; Repeat;
KW   Transferase.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330}.
FT   CHAIN         2    379       Protein
FT                                farnesyltransferase/
FT                                geranylgeranyltransferase type-1 subunit
FT                                alpha.
FT                                /FTId=PRO_0000119746.
FT   REPEAT      112    146       PFTA 1.
FT   REPEAT      147    180       PFTA 2.
FT   REPEAT      181    215       PFTA 3.
FT   REPEAT      216    249       PFTA 4.
FT   REPEAT      255    289       PFTA 5.
FT   COMPBIAS     22     31       Pro-rich.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330}.
FT   MOD_RES     373    373       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231}.
FT   VAR_SEQ      68    134       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_036468.
FT   MUTAGEN     164    164       K->N: Reduced activity.
FT                                {ECO:0000269|PubMed:8419339}.
FT   MUTAGEN     199    199       N->K: Reduced catalytic efficiency.
FT                                {ECO:0000269|PubMed:8494894}.
FT   CONFLICT    241    241       Y -> H (in Ref. 2). {ECO:0000305}.
FT   HELIX        66     68       {ECO:0000244|PDB:2H6F}.
FT   HELIX        70     72       {ECO:0000244|PDB:2H6F}.
FT   STRAND       87     90       {ECO:0000244|PDB:2H6F}.
FT   HELIX        94    109       {ECO:0000244|PDB:2H6F}.
FT   HELIX       114    126       {ECO:0000244|PDB:2H6F}.
FT   HELIX       131    143       {ECO:0000244|PDB:2H6F}.
FT   HELIX       148    161       {ECO:0000244|PDB:2H6F}.
FT   HELIX       166    179       {ECO:0000244|PDB:2H6F}.
FT   HELIX       185    195       {ECO:0000244|PDB:2H6F}.
FT   HELIX       200    213       {ECO:0000244|PDB:2H6F}.
FT   HELIX       216    218       {ECO:0000244|PDB:2F0Y}.
FT   HELIX       219    229       {ECO:0000244|PDB:2H6F}.
FT   HELIX       234    246       {ECO:0000244|PDB:2H6F}.
FT   HELIX       253    269       {ECO:0000244|PDB:2H6F}.
FT   HELIX       274    284       {ECO:0000244|PDB:2H6F}.
FT   TURN        285    287       {ECO:0000244|PDB:2H6F}.
FT   HELIX       289    291       {ECO:0000244|PDB:2H6F}.
FT   HELIX       293    302       {ECO:0000244|PDB:2H6F}.
FT   TURN        303    305       {ECO:0000244|PDB:2H6F}.
FT   HELIX       309    324       {ECO:0000244|PDB:2H6F}.
FT   HELIX       330    346       {ECO:0000244|PDB:2H6F}.
FT   HELIX       350    352       {ECO:0000244|PDB:2H6F}.
FT   HELIX       353    367       {ECO:0000244|PDB:2H6F}.
SQ   SEQUENCE   379 AA;  44409 MW;  E933CBA874AB92B9 CRC64;
     MAATEGVGEA AQGGEPGQPA QPPPQPHPPP PQQQHKEEMA AEAGEAVASP MDDGFVSLDS
     PSYVLYRDRA EWADIDPVPQ NDGPNPVVQI IYSDKFRDVY DYFRAVLQRD ERSERAFKLT
     RDAIELNAAN YTVWHFRRVL LKSLQKDLHE EMNYITAIIE EQPKNYQVWH HRRVLVEWLR
     DPSQELEFIA DILNQDAKNY HAWQHRQWVI QEFKLWDNEL QYVDQLLKED VRNNSVWNQR
     YFVISNTTGY NDRAVLEREV QYTLEMIKLV PHNESAWNYL KGILQDRGLS KYPNLLNQLL
     DLQPSHSSPY LIAFLVDIYE DMLENQCDNK EDILNKALEL CEILAKEKDT IRKEYWRYIG
     RSLQSKHSTE NDSPTNVQQ
//
